Glenmark Pharmaceuticals is introducing travoprost ophthalmic solution, 0.004% (ionic buffered solution), which is the ...

Glenmark Pharmaceuticals Inc, USA on Wednesday said it has launched Travoprost ophthalmic solution used in the treatment of ...

The global ophthalmic eye drop market is projected to grow from USD 17,271.8 million in 2024 to USD 25,876.4 million by 2034, ...

Travoprost Ophthalmic Solution USP, 0.004%, is used to lower intraocular pressure in patients with ocular hypertension or ...

Ophthalmic nonsteroidal anti-inflammatory agents may increase the risk of bleeding in ocular tissues following ophthalmic procedures (prescribing information, Volaten Ophthalmic, CIBA Vision ...

Glenmark Pharmaceuticals launches a generic glaucoma treatment, Travoprost ophthalmic solution, bioequivalent to Travatan Z.

Glenmark Pharmaceuticals Inc., USA is pleased to announce the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic ...

The repetitious use of ophthalmic medicines ... preservatives used in the medications and the total number of all eye drops used by the patient throughout the day. Owing to the potential adverse ...

这紧随Ocuphire以全股票交易收购Opus Genetics之后，通过增加OPGx-LCA5基因疗法候选药物和Phentolamine Ophthalmic Solution 0.75%来增强其产品线。 Ocuphire还报告了其眼科治疗药物RYZUMVI两项关键的III期临床试验的积极结果。该公司目前正在招募参与者进行VEGA-3 III期临床试验 ...

According to a statement from the firm, the Travoprost solution is bioequivalent and therapeutically equivalent to the ...